Skip to Main Content

Paper Details

Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Eur J Cancer
11
2023
Brain Tumor, IDH, IDH mutant, IDH wildtype, MGMT, MGMT promoter, O-methylguanine, O-methylguanine DNA methyltransferase, Patient, Patients, cancer, glioblastoma, isocitrate, isocitrate dehydrogenase, patients, tumours
Author NameAffiliation
Christine MarosiMedical University of Vienna
Martin GlasDivision of Clinical Neurooncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Partner Site University Medicine Essen
Elisabeth J RushingUniversity Hospital Zurich
Matthias PreusserMedical University of Vienna
Matthias PreusserMedical University of Vienna
Andreas von DeimlingUniversity Hospital Heidelberg, German Cancer Center (DKFZ)
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, USA Harvard Medical School
Guido ReifenbergerInstitute of Neuropathology, Heinrich Heine University and University Hospital Dusseldorf
Michael WellerUniversity Hospital and University of Zurich, Switzerland Clinical Neuroscience Center
  • 1 - 9

Datasets

Release 1.2